Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously
View HTML
Toggle Summary Predictive Oncology Announces $4.1 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously
View HTML
Toggle Summary Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology Reports That Its Wholly Owned Subsidiary, TumorGenesis, Has Sold Media to Two Top Research Medical Centers
EAGAN, Minn. , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc.
View HTML
Toggle Summary Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , Jan. 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously
View HTML
Toggle Summary Predictive Oncology Announces $3,074,007 Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology’s Wholly Owned Subsidiary Helomics completes integration of Quantitative Medicine
Our new PeDAL fee-for-service offering for Pharmaceutical companies will significantly improve the chances of translating discoveries into the clinic MINNEAPOLIS , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial
View HTML
Toggle Summary Predictive Oncology Hires Investor Relations Firm
MINNEAPOLIS , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has engaged Landon Capital to provide investor relations
View HTML
Toggle Summary Predictive Oncology Announces Cancellation of Special Meeting in December 2020
Reincorporation Proposal Received Overwhelming Support Among Shares Voted NEW YORK , Dec. 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) (the “Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today
View HTML